CommercialCoverageMedium impact
08.02.45a, Telisotuzumab vedotin-tllv (Emrelis™)
Independence Blue Cross·Oncology·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
A new commercial policy for Telisotuzumab vedotin-tllv (Emrelis™) has been updated and will be effective January 1, 2026. This is a pharmacy policy change that likely establishes coverage criteria, prior authorization requirements, or billing guidelines for this oncology medication.
Action Required
Before January 1, 2026: Billing team should review the full policy details at the provided URL to understand specific coverage criteria, prior authorization requirements, and billing procedures for Telisotuzumab vedotin-tllv (Emrelis™). Update pharmacy billing protocols and inform oncology providers of any new requirements.